Cancer
Conditions
Brief summary
The use of performance status and LDH in combination can predict patient survival more accurately than physician clinical impression or the patients' own feelings about their survival
Detailed description
Patients with incurable cancer frequently ask their doctors for an estimate of survival. Such estimates can assist patients in making decisions about how best to spend their time and energy. Survival estimates are also required when considering patients with incurable cancer for experimental treatments. However, such estimates are difficult to make. There is some data to suggest that a simple clinical measure, the performance status, combined with a laboratory blood test, the LDH, may assist in making the survival estimate more realistic. This study is designed to test if this is the case, using patients with metastatic lung, breast, colorectal, prostate, or pancreatic cancer or patients with cancer of unknown primary who have exhausted life-prolonging therapy. These patients will be asked to consent to entering this study. Their performance status will be assessed by the Karnofsky and WHO scales, they will be asked to have their blood tested for LDH and they and their doctor will be asked to estimate their survival. After study entry they will be allowed to receive palliative radiotherapy, surgery or systemic therapy as indicated including protocol treatment. After study entry, the only other requirement is that the date of the patients death be reported so that the duration of survival can be compared with the doctors and patients estimate and correlated with the performance status and LDH.
Interventions
None listed
Sponsors
New Mexico Cancer Research Alliance
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. All patients must be at least 18 years of age 2. All patients must have documented incurable metastatic cancer 3. All patients must have exhausted any treatments which are known to prolong survival in their disease, or have elected not to receive further life-prolonging therapy. Specifically, patients with the following are eligible: 1. Non-small cell lung cancer patients after third systemic therapy 2. Small cell lung cancer patients after second systemic therapy 3. Breast cancer patients after third cytotoxic therapy (does not include hormonal therapy) 4. Colorectal cancer patients after second systemic therapy 5. Hormone refractory prostate cancer patients after first cytotoxic therapy 6. Cancer of unknown primary 7. Pancreatic cancer patients after first systemic therapy 4. The use of systemic (chemotherapy, immunotherapy) or local treatments (XRT) for palliation of symptoms is allowed 5. Patients with a history of previous cancers are allowed 6. Patients with a history of other significant disease (e.g. heart disease, COPD, etc.) are allowed 7. All patients must sign informed consent
Exclusion criteria
1. Patients with acute or chronic leukemia, Hodgkin's disease, or non-Hodgkins lymphoma are excluded 2. Patients who do not sign informed consent are excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Progression | 2 years |
Countries
United States
Outcome results
None listed